secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001200375-24-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis reports Q4 net loss $7.2M; FY2023 net loss $76.2M; guides 2024 product rev $38-42M ex-PAXLOVID
--------------------------------------------------------------------------------

- Q4 net loss $7.2M ($0.10/sh); FY2023 net loss $76.2M ($1.12/sh). Excl PAXLOVID & impairment, adj FY net loss $50.8M ($0.74/sh).
- FY2023 total rev $70.1M (incl PAXLOVID); ex-PAXLOVID rev $62.0M (-2% YoY). Product rev ex-PAXLOVID $34.8M (-16% YoY).
- Q4 total rev $26.6M; ex-PAXLOVID rev $18.4M (+42% YoY). R&D rev $8.5M.
- 2024 guidance: Product rev $38-42M ex-PAXLOVID, R&D rev $18-22M, product GM 58-63%. Cash runway to positive CF around end-2026.
- Recent deals: Nestlé up to $45M milestones for CDX-7108; $40M Innovatus loan; Roche exclusive license for dsDNA ligase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000007/0001200375-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000007/cdxs-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001200375-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer